Chronic Myeloid Leukemia
What's New
Last Posted: Nov 03, 2022
- Mutational Landscape of Patients Referred for Elevated Hemoglobin Level.
Bhai Pratibha et al. Current oncology (Toronto, Ont.) 2022 29(10) 7209-7217 - Comparing machine learning algorithms to predict 5-year survival in patients with chronic myeloid leukemia.
Shanbehzadeh Mostafa et al. BMC medical informatics and decision making 2022 22(1) 236 - Genetic counseling and carrier screening in candidates for gamete donation at a Portuguese center.
Soares Célia Azevedo et al. JBRA assisted reproduction 2022 - Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.
Adnan-Awad Shady et al. Leukemia & lymphoma 2021 1-15 - The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes.
Sasaki Koji et al. American journal of hematology 2020 Nov - Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper.
Soverini Simona et al. Journal of hematology & oncology 2019 12(1) 131 - Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia.
Pagani Ilaria S et al. Leukemia & lymphoma 2020 Jun 1-3 - An Evaluation of the Utility of Big Data to Supplement Cancer Treatment Information: Linkage Between IQVIA Pharmacy Database and the Surveillance, Epidemiology, and End Results Program.
Tran Quyen et al. Journal of the National Cancer Institute. Monographs 2020 May 2020(55) 72-81 - Why Aren't Cancer Drugs Better? The Targets Might Be Wrong
C Zimmer, NY Times, September 13, 2019 - Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice.
Almeida Antonio et al. Acta medica portuguesa 2019 Aug 32(7-8) 550-557 - Clinical Evaluation of Massively Parallel RNA Sequencing for Detecting Recurrent Gene Fusions in Hematologic Malignancies.
Kim Borahm et al. The Journal of molecular diagnostics : JMD 2018 Oct - Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.
Radich Jerald P et al. Journal of the National Comprehensive Cancer Network : JNCCN 2018 Sep 16(9) 1108-1135 - Future of Evidence Synthesis in Precision Oncology: Between Systematic Reviews and Biocuration
SM Boca et al, JCO Precision Oncology, September 2018 - Local Coverage Determination (LCD): Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases (L37606)
The U.S. Centers for Medicare & Medicaid Services - Molecular biology as a tool for the treatment of cancer.
de Castro Sant' Anna Carla et al. Clinical and experimental medicine 2018 Jul - Identification of Prognostic and Susceptibility Markers in Chronic Myeloid Leukemia Using Next Generation Sequencing.
Shokeen Yogender et al. Ethiopian journal of health sciences 2018 Mar 28(2) 135-146 - Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high risk disease.
Branford Susan et al. Blood 2018 Jul - Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update.
Ankathil Ravindran et al. Pharmacogenomics 2018 Mar - Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: a systematic review and meta-analysis.
Cargnin Sarah et al. Pharmacological research 2018 Feb - TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome.
Weich Natalia et al. Blood cells, molecules & diseases 2016 Jul 59129-33 - Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions.
Vasko Theresa et al. International journal of molecular sciences 2017 Oct 18(11) - Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents.
Millot Frédéric et al. Cancer 2017 Sep 123(18) 3609-3616 - Conversion, Correction, and International Scale Standardization: Results From a Multicenter External Quality Assessment Study for BCR-ABL1 Testing.
- Chronic myeloid leukemia
From NCATS Genetic and Rare Diseases Information Center - Philadelphia-negative chronic myeloid leukemia
From NCATS Genetic and Rare Diseases Information Center
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Content Summary
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Eclampsia
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Glomerulonephritis
- Graves Disease
- Hemophilia
- Huntington Disease
- Microcephaly
- Myasthenia Gravis
- Phenylketonuria
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Content source: